Brief: Obseva Announces Publication Of Abstracts From Phase 2B Edelweiss Trial Of Linzagolix In Endometriosis
22/04/2020 22:35
April 22 (Reuters) - Obseva SA OBSN.S :
* OBSEVA ANNOUNCES PUBLICATION OF ABSTRACTS FROM PHASE 2B
EDELWEISS TRIAL OF LINZAGOLIX IN ENDOMETRIOSIS
* OBSEVA SA - SIGNIFICANT IMPROVEMENT IN QUALITY OF LIFE
OUTCOMES
MAINTAINED OR INCREASED AFTER 52 WEEKS OF TREATMENT WITH
LINZAGOLIX
* OBSEVA SA - SMALL, EXPECTED, NON-CLINICALLY RELEVANT
INCREASES
IN SERUM LIPIDS OBSERVED AT 12 WEEKS GENERALLY STABLE AT 52
WEEKS
Source text for Eikon: ID:nGNE4zX8Cg
Further company coverage: OBSN.S
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Obseva SA
See all newsBrief: Obseva Announces Wind-Down Of Operations And Likely Not Going To Be Able To Satisfy Requirements For Maintaining Its Listing
Brief: Obseva Applies For Moratorium To Facilitate Pivotal Deals
Brief: Obseva SA Says Xoma Will Receive Full Worldwide Rights On Ebopiprant Following Termination Of License Agreement With Organon
Brief: Obseva Appoints Fabien De Ladonchamps As Chief Executive Officer Effective May 1, 2023
Brief: Obseva Announces Change Of Central Securities Depositary